WWB Windward Bio Group AG Common Shares
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.…
Industry Peers
BiotechnologyKey Statistics
About Windward Bio Group AG Common Shares (NASDAQ: WWB)
›
Windward Bio Group AG Common Shares (NASDAQ: WWB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 28.50 USD on 13 November 2026. Its 52-week range is 18.35 USD to 33.99 USD: the price is 16.1% below the high and 55.3% above the low.
Its market capitalisation is 1.65B USD.
Windward Bio Group AG Common Shares reports return on equity of -25.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 185.99M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.